The Kettering Health Pharmacy and Therapeutics Committee (P&T) has approved the use of Remdesivir for Incidental COVID findings in inpatients. Two order sets will be available based on indication. Each panel will include guidelines for use and the recommended duration of therapy.
The two new order sets will go live, today, 1/31/2022.
